RACHESKY MARK H MD

Mark Rachesky, M.D., has maintained a decidedly one-sided posture in his disclosed trading over the period covered by recent Form 4 filings, with a cumulative buy-side value of approximately $5.0 million against zero open-market sales. The overwhelming majority of that capital deployment occurred on June 2, 2025, when he executed two open-market purchases in STRZ totaling roughly $5.0 million—$4.42 million and $582,895, respectively. That concentrated accumulation stands in contrast to his activity in LION, where a cluster of transactions on July 8, 2026, included both purchases and sales, though the reported dollar values for those trades were listed as zero, making the net direction ambiguous. Across all three tickers—STRZ, LION, and TWI—his trading pattern is dominated by non-discretionary or compensatory events: grants (code A), option exercises (code M), and tax-withholding dispositions, which collectively account for most of the 49 total filings. The recent cadence reinforces a bias toward acquisition rather than distribution. In the nine most recent buy-coded events, only the STRZ purchases from June 2025 carried a meaningful price tag; the remaining buys in LION were recorded at zero value, suggesting either nominal share counts or data omissions. Meanwhile, the five sell-coded events were all LION transactions on the same July 2026 date, also valued at zero, which prevents a clear read on whether he is trimming a position or merely executing routine adjustments. His only notable sell-side activity in the broader window is absent—no open-market sales (code S) with positive dollar values appear anywhere in the record, reinforcing that his disclosed intent has been overwhelmingly accumulative, particularly in STRZ, where the June 2025 purchases dwarf all other activity. The compensatory grants and exercises—such as the $179,998 award in TWI on June 23, 2026, and the $139,900 option exercise in TWI on February 9, 2026—are mechanical by nature and do not reflect discretionary conviction. What stands out is the singular, large open-market buy in STRZ, which, when paired with the absence of any corresponding sales, suggests a deliberate concentration of capital in that name. The LION trades, while frequent, lack the dollar transparency needed to assess their significance, leaving the overall narrative as one of a buyer who has committed real money to a single ticker while treating the others as vehicles for compensation-driven activity.